Sold as Questran, Questran Light. Every FDA application for this active ingredient: 2 branded and 26 generic.
As of Nov 14, 2026, FDA lists 28 applications for Cholestyramine (sold as Questran, Questran Light), first approved Aug 3, 1973, with 0 new uses approved and 0 published complete response letters.
| Cholestyramine Light | Part D | $14.2M | -1% | 72,469 |
| Prevalite | Part D | $2.1M | -52% | 10,981 |
| Questran Light | Part D | $4K | New | 11 |
| A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple SclerosisMultiple Sclerosis · Sanofi | Phase 3 | Not yet recruiting | Nov 12, 2026 |
| PFAS Clinical TrialEnvironmental Exposure · Emory University | Phase 2 | Not yet recruiting | Sep 23, 2026 |
| LATAM LOWERS LDL-CHypercholesterolaemia · Novartis Pharmaceuticals | Phase 4 | Recruiting | Jul 15, 2024 |
| Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic CancerAdvanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 · City of Hope Medical Center | Phase 1 | Active, not recruiting | Jun 12, 2024 |
| Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisMultiple Sclerosis · Sanofi | Phase 3 | Active, not recruiting | Nov 21, 2023 |
| Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female PatientsObesity, Abdominal, Diabetes · Centre Hospitalier Universitaire de Nice | Not applicable | Recruiting | Aug 1, 2023 |
| Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic MalignanciesAcute Graft Versus Host Disease, Hematopoietic and Lymphoid System Neoplasm · City of Hope Medical Center | Phase 1 | Recruiting | Jul 5, 2022 |
| Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American PatientsSmoldering Plasma Cell Myeloma · City of Hope Medical Center | Phase 2 | Active, not recruiting | Aug 20, 2021 |
| Aug 3, 1973 | QuestranNDA 16640 · New dosage form | Bristol Myers | 51 | Discontinued |
| Dec 5, 1988 | Questran LightNDA 19669 · New dosage form | Bristol Myers | 16 | Discontinued |
| Feb 22, 1996 | PrevaliteANDA 73263 | Aiping Pharm Inc | 10 | Marketed |
| Aug 15, 1996 | CholestyramineANDA 74557 | Epic Pharma LLC | 6 | Marketed |
| Aug 15, 1996 | Cholestyramine LightANDA 74558 | Epic Pharma LLC | 5 | Marketed |
| Aug 15, 1996 | LocholestANDA 74561 | Chartwell Rx | 4 | Marketed |
| Aug 15, 1996 | Locholest LightANDA 74562 | Chartwell Rx | 4 | Marketed |
| Oct 2, 1996 | CholestyramineANDA 74554 | Ani Pharms | 6 | Discontinued |
| Jul 9, 1997 | CholestyramineANDA 74771 | Ivax Sub Teva Pharms | 0 | Discontinued |
| May 28, 1998 | CholestyramineANDA 74347 | Teva | 1 | Discontinued |
| May 28, 1998 | Cholestyramine LightANDA 74348 | Teva | 1 | Discontinued |
| Sep 30, 1998 | Cholestyramine LightANDA 74555 | Teva Pharms | 0 | Discontinued |
| Aug 26, 2005 | Cholestyramine LightANDA 77203 | Ph Health | 1 | Marketed |
| Aug 26, 2005 | CholestyramineANDA 77204 | Ph Health | 0 | Marketed |
| Apr 25, 2017 | Cholestyramine LightANDA 202902 | Zydus Pharms | 0 | Marketed |
| Jul 2, 2018 | CholestyramineANDA 202901 | Zydus Pharms | 1 | Marketed |
| Apr 6, 2020 | CholestyramineANDA 211119 | Ajanta Pharma Ltd | 1 | Marketed |
| Nov 12, 2020 | Cholestyramine LightANDA 209599 | Pharmobedient Cnsltg | 0 | Marketed |
| Mar 9, 2021 | CholestyramineANDA 209597 | Pharmobedient | 0 | Marketed |
| Oct 19, 2021 | Cholestyramine LightANDA 211799 | Alkem Labs Ltd | 0 | Marketed |
| Oct 19, 2021 | CholestyramineANDA 211856 | Alkem Labs Ltd | 0 | Marketed |
| Jan 21, 2022 | CholestyramineANDA 214877 | Aiping Pharm Inc | 0 | Marketed |
| Oct 31, 2024 | Cholestyramine LightANDA 209109 | Macleods Pharms | 0 | Discontinued |
| Nov 21, 2024 | CholestyramineANDA 207294 | Macleods Pharms | 0 | Marketed |
| Mar 5, 2026 | CholestyramineANDA 219318 | Micro Labs | 0 | Marketed |
| — | CholybarANDA 71621 | Parke Davis | 0 | Discontinued |
| — | CholybarANDA 71739 | Parke Davis | 0 | Discontinued |
| — | QuestranANDA 73403 | Apothecon | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Teva
Zydus Pharms
Parke Davis
Apothecon